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S U M M A R Y
Objective: The DEFB103 gene encodes human b-defensin 3, which has a high activity against
Staphylococcus aureus. In the general population 20% are persistent nasal carriers of S. aureus, which
is a problem for their general health. DEFB103 shows extensive variation in copy number. Copy number
variations (CNVs) are believed to play a role in susceptibility to certain diseases. The possible
associations between CNVs, mRNA, and nasal S. aureus carriage status were investigated.
Methods: We used the pyrosequencing-based paralog ratio test to determine theDEFB103 copy number.
Nasal swabs were collected for RNA and S. aureus determination. S. aureus genotypes were determined
by spa typing, and real-time PCR was used to determine DEFB103 mRNA expression.
Results: TheDEFB103 CNV varied from 2 to 8 copies per diploid genome. No signiﬁcant difference in copy
number was observed among the groups. We found 74% of the volunteers to be non-carriers, 20% to be
persistent carriers, and 6% to be intermittent carriers. The S. aureus isolates linked tomore than 16 clonal
lineages. mRNA expression varied extensively, but no signiﬁcant differences were observed between the
groups. We did not ﬁnd a linear correlation between CNV and mRNA expression.
Conclusions: The results indicate that DEFB103 CNV does not inﬂuence S. aureus carrier status.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j id1. Introduction
The innate immune system is the primary defense mechanism
against bacterial infections.1 To establish an infection, pathogenic
organisms need to penetrate the barriers of the innate immune
system, including the physical barriers consisting of the skin and
epithelia.
Among the key factors involved in innate defense are
antimicrobial peptides (AMPs). AMPs belong to a group of peptides
that possess activity against bacteria, viruses, and fungi.2,3 In
vertebrates they are expressed at the primary barriers of the
organism, such as the skin andmucosal epithelia, where they act to
prevent pathogen colonization of host tissues.2,4,5
Defensins, a group of AMPs, are small cationic and cysteine-rich
peptides with a molecular mass between 3 and 5 kDa.6,7 They are
classiﬁed into two main categories based on the linking pattern of
their six cysteine residues: a- and b-defensins.8 Mammalian a-
defensins are predominantly found in neutrophils9,10 and in the
small intestinal Paneth cells,11 whereas the b-defensins have been
isolated from both leukocytes and epithelial cells.12–16* Corresponding author. Tel.: +45 3268 32 68x8190; fax: +45 3268 3132.
E-mail address: psa@ssi.dk (P.S. Andersen).
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antibacterial activity against Staphylococcus aureus13 and to
possess other biological activities, including chemokine-like
activities,17 immunomodulating properties,18 and bridging of
the innate and the adaptive immune systems through dendritic-
and T-cell CCR6.19
The genes encoding hBD-3 and a number of other b-defensins
are clustered on chromosome 8p23.1,20 a genomic region that
contains extensive genetic copy number variants (CNVs).21
DEFB103, the gene encoding hBD-3, varies from 2 to 12 copies
per diploid genome in the general population, with most
individuals having between 2 and 7 copies.21 CNVs are believed
to play an important role in susceptibility to certain diseases,
including psoriasis22 and Crohn’s disease.23,24 Evidence that CNVs
are positively correlated to mRNA and peptide expression has
recently been published,21,25,26 indicating that a high copy number
results in a high level of gene product.
Nasal carriage of S. aureus is an important risk factor for
infection in both community and hospital settings.27 Longitudinal
studies have shown that the healthy adult population can be
differentiated into three carrier types according to their carriage
pattern: 10–20% have been determined to be persistent carriers
(PC), 30–50% are colonized intermittently and have been deter-
mined to be intermittent carriers (IC), and the remaining fraction
are non-carriers (NC), who are believed never to carry S. aureus inses. Published by Elsevier Ltd. All rights reserved.
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young children,34 dialysis patients,35 and diabetic patients.36 The
reason for this variable tropism is still not clear.
PC are at higher risk for the development of S. aureus
infections.37,38 The IC risk of infection is similar to that of NC,39
suggesting that perhaps only two groups should exist: persistent
carriers and ‘other’.40
PC are often colonized by a single strain of S. aureus over a long
period of time,41 while IC tend to carry different strains for briefer
time-periods, indicating that bacterial factors could be involved in
the infection pattern. Cell wall teichoic acid, lipoteichoic acid, and
ﬁbronectin-binding proteins have been shown to represent major
ligands in the adherence of S. aureus to epithelial cells and to be
important in the colonization process.42–44
Host genetics also appear likely to play a role in nasal S. aureus
carriage due to the difference in carriagewithin the population and
because different ethnic groups exhibit variations in carriage
rates.45 A community-based carriage study has demonstrated a
family predisposition to nasal carriage of S. aureus that cannot be
explained solely on the basis of exposure to a common reservoir of
bacteria.46 Cole et al. demonstrated that nasal secretions obtained
from individuals colonized with S. aureus lacked antimicrobial
activity against S. aureus in vitro, whereas ﬂuid from non-carriers
were bactericidal.47 Recent studies have also shown that
individuals deﬁcient in the interleukin (IL)-1 receptor-associated
kinase 4 (IRAK4) and myeloid differentiation primary response
gene 88 (MyD88) experience recurrent infections with Streptococ-
cus pneumoniae, S. aureus, and Pseudomonas aeruginosa.48,49 Other
studies have furthermore shown that a polymorphism in the
glucocorticoid receptor gene is associated with differences in the
immune state inﬂuencing the S. aureus carriage state.50 Also, the
IL4-524 C/C phenotypewas recently found to be associatedwith an
increased risk of persistent carriage, whereas a speciﬁc haplotype
of the C-reactive protein (CRP) gene was overrepresented in
individuals who were not colonized.51
This study addresses hBD-3 in relation to nasal S. aureus
carriage, including the genetic association of DEFB103 CNVs and
mRNA expression.
2. Materials and methods
2.1. Participants
Employees from Statens Serum Institut, Copenhagen, Denmark
were invited to participate in the study. A criterion for participa-
tionwas that the participant should be in good health at the time of
study inclusion. Before providing a sample, each participant was
asked to ﬁll out a questionnaire regarding smoking status, use of
antibiotics, diabetes, chronic infections (eczema, psoriasis, atopic
dermatitis, etc.), age, gender, ethnicity, and illness related to the
throat, nose, lungs or skin. Furthermore participants were asked
whether theyworkedwithmicroorganisms, and if so which one(s).
Participants were excluded from the study if they suffered from
fever, psoriasis, eczema or other chronic diseases, illnesses related
to the throat, lungs, nose or skin, or were taking antibacterial or
immunosuppressive medication. All participants were ethnically
Danish. Of 178 who agreed to participate, 169 fulﬁlled the criteria.
Two samples were collected from each individual, a week apart,
for determination of S. aureus nasal colonization, according to the
study of Nouwen et al.52 At each S. aureus sampling, samples were
also taken from the nose for mRNA analysis. Saliva for DNA
extractionwas only collected at the ﬁrst sampling. The participants
were asked not to drink, smoke, or eat half an hour before the
sample was collected. The samples were collected by the same
person over a 12-month period.2.2. Ethical considerations
The study was approved by the local ethics committee (project
numbers 16739 and 19246) and The Danish Data Protection
Agency (project number 2007-54-0311). All participants received
oral and written information from the investigator, and informed
consent was obtained from all participants according to Danish
law.
2.3. DNA collection and extraction
Two milliliters of saliva was collected from each participant in
an Oragene DNA container (DNA Genotek, Kanata, ON, Canada).
The sample was shaken for a short time and heated to 50 8C for 2 h
in an air incubator, according to the manufacturer’s instructions.
DNA was puriﬁed according to the manufacturer’s protocol. In
brief, 500ml of the sample was transferred to an Eppendorf tube
(Eppendorf, Hamburg, Germany); 20 ml Oragene DNA puriﬁer
(DNA Genotek) was added, and this was then vortexed and
incubated on ice for 10 min and centrifuged at 15 000 g for 15 min.
The supernatant was transferred to a new Eppendorf tube and
500ml of 96% room-temperature ethanol was added. The tube was
inverted 10 times and allowed to stand at room temperature for
10 min, followed by centrifugation at 15 000 g for 2 min. The
supernatant was discarded and the pellet was washed in 250ml of
70% ethanol. One hundred microliters of sterile water (Invitrogen,
Paisley, UK) was added to dissolve the DNA pellet. The tube was
vortexed for at least 5 s and incubated at 50 8C for 1 h for complete
hydration.
DNA concentration was measured using a NanoDrop-1000
(Thermo Scientiﬁc, Waltham, MA, USA). Puriﬁed DNA was stored
at  80 8C for later analysis.
2.4. RNA collection and extraction
Nasal samples were collected with cotton wool swabs (DNA
Genotek). Both the left and the right anterior nares were swabbed
by rubbing the swab four times. The swabwas added to a container
containing a solution for RNA stabilization (DNA Genotek) and
heated to 50 8C for 2 h in an air incubator, according to the
manufacturer’s instructions. RNA was puriﬁed according to the
manufacturer’s guidelines using an RNeasy Micro kit (Qiagen,
Hilden, Germany). A 250-ml sample was transferred to a 1.5-ml
Eppendorf tube, heated to 90 8C for 15 min, and allowed to cool to
room temperature. A 1/25th volume of Oragene RNA Neutralizer
solution (DNA Genotek) was added, and the sample was incubated
on ice for 10 min, followed by centrifugation at 20 000 g for 3 min.
The supernatant was transferred to a new 1.5-ml Eppendorf tube
and 500 ml of ice-cold 96% ethanol was added. After incubation at
20 8C for 30 min, the sample was centrifuged at 20 000 g for
3 min. The supernatantwas removed and discarded. The pellet was
dissolved in 350ml of RLT buffer from the RNeasy Micro kit
(Qiagen); 350ml of 70% ethanol was added and the tube was
vortexed. Then the Qiagen RNeasy clean-up procedure was
followed; 35ml of RNase-free water was used for elution of the
RNA from the column membrane.
RNA concentration was measured using the Bioanalyzer-2100
(Agilent Technologies, Santa Clara, CA, USA). Puriﬁed RNA was
stored at 80 8C until further analysis.
2.5. Microbiological analysis and Staphylococcus aureus
determination
Nasal swabs were taken according to a standard operating
procedure, as described elsewhere.41 The volunteers were
screened for nasal carriage of S. aureus on two occasions, one
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Both the left and the right anterior nares were swabbed by rubbing
the swab four times around the inside of each nostril, while
applying an even pressure and rotating the swab without
interruption. Participants were identiﬁed as NC if two successive
nasal swabs were negative for S. aureus, as IC if they had only one
positive swab sample, and as PC if they had two successive positive
nasal swabs.52
Immediately after the sample was collected, the swabs were
cultured on chromID S. aureus plates (bioMe´rieux, Rhoˆne-Alpes,
France) and incubated for at least 24 h at 37 8C. Identiﬁcation of S.
aureus was based on the color of the colony. Suspected colonies
were cultured overnight on blood agar plates (SSI Diagnostika,
Hillerød, Denmark). S. aureus was identiﬁed by a latex agglutina-
tion test (bioMe´rieux). All S. aureus isolates were plated overnight
on blood agar plates (SSI Diagnostika) and stored at 80 8C in
glycerol-containing liquid medium (SSI Diagnostika).
All isolates were characterized by spa typing, and clonal
complex association was determined using http://spaserver.ri-
dom.de and by comparing multilocus sequence typing (MLST)
mapping on previous isolates with similar or related spa-types
with subsequent clustering using eBURST v3.
2.6. Copy number determination (pyrosequencing-based paralog
ratio test)
The paralog ratio test (PRT) was carried out essentially as
described previously.53,54 The principles of pyrosequencing
based-PRT (P-PRT) have recently been described elsewhere.55,56
In brief, one primer pair was used to amplify two different
products, one product on chromosome 8 (the DEFB region,
target-gene and variable in copy number) and a second product
on chromosome 21 (HSPD21, reference gene and constant in
copy number).53,54 The two PCR products differed in sequence at
10 positions. One of these positions at which the amplicons
differed was used to quantify the two chromosomal regions
against each other by pyrosequencing across it. Primers for the
pyrosequencing assay were designed using the PSQ assay design
software version 1.0.6 (Qiagen). For the PCR, 20 ng of template
DNA in a total volume of 50 ml was used, with the following PCR
primers: DEFB103f (50-GAGGTCACTGTGATCAAAGAT-30) and
DEFB103r (50-biotin-AACCTTCAGCACAGCTACTC-30). Agarose
gel electrophoresis was used to verify the PCR product before
pyrosequencing.
Pyrosequencing was carried out on 40 ml of the PCR product,
using a sequencing primer (50-AGGTCACTGTGATCAAAGAT-30) on
the PSQ 96 MA Pyrosequencer, according to the manufacturer’s
recommendations (Qiagen). The relative percentages of the two
variants were calculated by the accompanying software and used
for the gene copy number determination. Positive controls from
Coriell Cell Repositories with known numbers of copies were
included in each run (NA07048: 4 copies; NA10846: 5 copies;
NA10847: 7 copies, and NA10861: 3 copies) and used to generate a
correction curve by linear regression. Corrected copy number
estimates were calculated for each sample using this run-speciﬁc
regression equation. A ‘no template control’ was included in each
run.Table 1
Participant characteristics. A total number of 169 persons fulﬁlled the criteria for partici
According to participant nasal Staphylococcus aureus status they were divided into eith
No. of NC No. of PC
Participants 125 34
Age, years 26–87 (mean: 40) 26–57 (mean:
No. of males 44 162.7. Determination of DEFB103 mRNA expression
cDNA was synthesized using the High-Capacity cDNA Reverse
Transcription kit as recommended by the manufacturer (Applied
Biosystems, Foster City, CA, USA). Ten microliters of RNA was
diluted with 2X RT Master Mix (Applied Biosystems). The reverse
transcriptase PCR was performed with a step at 25 8C for 10 min,
followed by 37 8C for 2 h and a ﬁnal step at 85 8C for 5 s. A
contamination control sample without reverse transcriptase was
included in each run. DEFB103 mRNA levels were determined by
quantitative real-time PCR (QPCR) normalized to b-actin mRNA
using pre-developed TaqMan primer/probe assay reagents from
Applied Biosystems (Applied Biosystems, DEFB103 (FAM-labeled),
catalog No. Hs00218678_m1; Human b-actin (VIC-labeled),
catalog No. 4326315E).
cDNA samples were ampliﬁed in a duplex setup with 1X Gene
ExpressionMasterMix (Applied Biosystems). All samples were run
in triplicate. Every plate included a ‘no template control’ and a
calibrator. PCR was performed using conditions suggested by the
manufacturer: 10 min at 95 8C, followed by 40 cycles of 95 8C for
15 s and 60 8C for 60 s, on an MX3000P real-time QPCR instrument
(Stratagene, now part of Agilent Technologies).
2.8. Statistical analysis
Statistical analysis was performed using GraphPad InStat 3
(version 3.06; GraphPad Software, La Jolla, CA, USA) and Microsoft
Excel. All tests were two-sided and the signiﬁcance level was set at
5%.
3. Results
3.1. Participant characteristics
A total of 178 persons agreed to participate in the study. One
hundred and sixty-nine of these – 63 men (37%) and 106 women
(63%) – fulﬁlled the criteria for participation. The age ranged from
26 to 87 years, with a mean age of 40 years. Participant
characteristics are summarized in Table 1.
3.2. Staphylococcus aureus nasal colonization
The participants were distributed into three groups based on
their nasal S. aureus carrier status. Of the 169 participants, 34
(20%) were determined to be PC with two successive positive
nasal swabs, 10 (6%) had only one positive swab and were
determined to be IC, and the remaining 125 (74%) were NC
(Table 1).
Sixteen (47%) of the PC and three (30%) of the IC were men. In
total, 25% of the men included were PC, whereas only 17% of the
women were PC. This difference was not statistically signiﬁcant
(p = 0.2622, Chi-square).
The mean age in the NC group was 40 years and in both the PC
and IC groups was 39 years. There was no signiﬁcant difference in
age between the groups (p = 0.8053, one-way analysis of variance
(ANOVA)).pation. A total of 63 men and 126 women participated. The mean age was 40years.
er non-carriers (NC), persistent carriers (PC) or intermittent carriers (IC)
No. of IC Total
10 169
39) 29–54 (mean: 39) 26–87 (mean: 40)
3 63
[(Figure_1)TD$FIG]
Figure 1. Genomic copy number distribution of DEFB103 for the three groups. The
DEFB103 copy number varied from 2 to 8 copies per diploid genome in the three
groups. Most people had between 3 and 6 copies. NC, non-carrier; PC, persistent
carrier; IC, intermittent carrier.
P. Fode et al. / International Journal of Infectious Diseases 15 (2011) e388–e394 e391Among the 169 persons, ﬁve worked with S. aureus regularly;
compared to the rest of the group, no difference was observed
among the ﬁve persons with regard to carrier rates (p > 0.05, Chi-
square test).
The S. aureus positive nasal swabs encompassed a total of 36 spa-
types thatwere linkedto16different clonal complexes (Table2). The
most frequently observed spa-type was t230. Two unrelated spa-
typeswerenot related toanycommonly encounteredclonal lineage.
One PC carried two different and unrelated S. aureus isolates at each
of the two samplings and was thus designated as an IC. All other PC
carried the same subtype of S. aureus.
3.3. DEFB103 gene copy number
The copy number varied from 2 to 8 copies per diploid genome,
with most individuals possessing copy numbers of between 3 and
6 copies. The frequency distributionwas comparable in the groups,
as illustrated in Figure 1.
The mean and median DEFB103 CNV was similar in all three
groups (NC: mean = 4.8, median = 4.7; PC: mean = 4.6, medi-
an = 4.6; IC:mean = 4.6,median = 4.1) and no signiﬁcant difference
was observed between the three groups (p > 0.5203, one-way
ANOVA) (Table 3). In addition, no statistical difference was found
between PC and the combination of IC and NC (p > 0.31, t-test).
3.4. Expression of b-defensin mRNA in nasal secretions
Using QPCR, the mRNA expression levels of hBD-3 were
determined. Figure 2 shows the variation in DEFB103 mRNATable 2
The spa-type and clonal complex of the Staphylococcus aureus nasal isolates. Thirty-six d
t230 was the most frequently observed spa-type
Clonal complex
spa-type CC1 CC101 CC12 CC121 CC15 CC182 CC20 CC22
t002
t005 2
t008
t012
t021
t024
t026
t065
t084 4
t091
t1265
t144 4
t148
t150 2
t160 4
t166
t171 2
t189 2
t2096
t216
t2271
t230
t267
t273 2
t3327
t369
t408 2
t449 1
t493 1
t6515 3
t6517
t726
t731 2
t789
t922 2
t179expression in the samples. Both samplings are plotted. The relative
DEFB103mRNA expression levels varied from 0 to 141 compared to
the calibrator. The majority of the expression levels were in the
range of 0 to 50, with only fourmeasurements above 50 (2.4%). The
mean levels in the three groups were 4.31 for PC, 5.80 for IC, and
4.95 for NC. Overall there was no signiﬁcant variation in mRNA
expression between the three groups (p = 0.4693, one-way
ANOVA), as illustrated in Figure 2. Comparison of PC with the
combination of IC and NC showed no signiﬁcant variation either
(p > 0.7; Mann–Whitney test).ifferent spa-types were identiﬁed and 16 different clonal complexes were present;
CC30 CC45 CC5 CC59 CC7 CC72 CC8 CC97 Unknown
2
2
4
2
1
4
2
2
2
2
1
1
2
2
5
1
2
2
2
2
1
1
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Figure 2. DEFB103 mRNA expression in the three groups. The expression levels
varied from 0 to 141, with the majority of people having between 0 and 50.
Indicated are the standard errors of the means (SEM). No signiﬁcant differences
were observed between the groups (p > 0.05, one-way ANOVA). NC, non-carrier;
PC, persistent carrier; IC, intermittent carrier.
Table 3
DEFB103 gene copy number variation in the three groups. The mean and median
copy numbers and the minimum and maximum values of the copy number within
each group are shown. No statistically signiﬁcant differences were observed among
the three groups (p>0.05, one-way ANOVA).
NC PC IC Total
No. 125 34 10 169
Mean copy number 4.8 4.6 4.6 4.8
Median copy number 4.7 4.6 4.1 4.7
Min/max 2/8 2/7 4/7 2/8
NC, non-carriers; PC, persistent carriers; IC, intermittent carriers.
Table 4
Mean mRNA expression in the three groups. The mean values are given for the two
samples taken. Inter-sampling differences were evaluated for each group by
Wilcoxon matched paired test. For NC and IC there was a signiﬁcant difference in
the DEFB103 expression between the two samplings
NC PC IC Total
mRNA fold
change (mean)
3.4 6.5 4.0 4.7 8.8 2.8 5.4 4.7
Inter-sampling difference p<0.05 p>0.05 p<0.05
NC, non-carriers; PC, persistent carriers; IC, intermittent carriers.
[(Figure_3)TD$FIG]
Figure 3. Correlation between DEFB103 mRNA expression and genomic copy
number for non-carriers (NC), persistent carriers (PC), and intermittent carriers (IC).
A high variation of mRNA expression was seen within each copy number. No
signiﬁcant linear correlation was observed between mRNA and genomic copy
number in any of the groups (p > 0.05, Spearman’s rank correlation coefﬁcient).
P. Fode et al. / International Journal of Infectious Diseases 15 (2011) e388–e394392The Wilcoxon matched paired test was used to evaluate
differences in mRNA expression between the two samples taken
from each individual. The data are summarized in Table 4. An inter-
sampling variation of mRNA expression was observed in the NC
group (p = 0.001) and in the IC group (p = 0.0469), but no
statistically signiﬁcant variation was observed in the PC group
(p > 0.05).
3.5. Relationship between copy number and mRNA expression
Combining the results from the copy number determination
and mRNA expression, a possible linear association between these
two factors was tested. No linear correlation was found between
CNV and mRNA expression (NC: p = 0.8911; PC: p = 0.3728; IC:
p = 0.9031, Spearman’s rank correlation). Figure 3 shows the CNV
as a function of mRNA expression. A high variation in expression
was observed within each copy number.
A possible correlation between CNV and mRNA expression for
samples having between 2 and 5 copies was also investigated, but
no linear correlation was observed: NC: p = 0.0591; PC: p = 0.9087;
IC: not possible since lowest copy number was 4, Spearman’s rank
correlation).4. Discussion
In this study, the antimicrobial peptide hBD-3 was investigated
in relation to S. aureus nasal carriage. hBD-3 is a component of the
innate immune system that is expressed in epithelial tissue and
has a strong antibacterial activity against S. aureus.13 This could
suggest that the expression of hBD-3 would inﬂuence nasal
carriage of S. aureus.
Nasal samples were collected from 169 healthy volunteers to
determine their S. aureus carriage status, DEFB103 gene copy
number, and DEFB103 mRNA expression.
S. aureus nasal carriage was determined by taking two
successive samples, one week apart, as has been suggested for a
reliable determination of S. aureus carriage state.52 We found the
persistent carrier rate to be 20%, which is in agreement with other
reports from Western European adult communities.39,57 The
carriage frequency was higher in men than in women, but the
difference was not signiﬁcant, which in part is due to the small
number of samples. Other studies have found that men are more
frequently carriers than women.33
The percentage of intermittent carriers was 6%. This is a lower
percentage than that found in other studies,30–32,58 butmay be due
to the small size of the cohort.
A number of the participants were working with S. aureus on a
daily basis. We found no difference in the carrier rate with regard
to working with or without S. aureus, which is in agreement with
earlier ﬁndings58 from Statens Serum Institut.
Clonal relations of the analyzed S. aureus isolates were highly
diverse. None of the samples resembled the genetic composition
of the community-associated MRSA in Denmark.59 We found 36
spa-types in the samples linking to 16 different clonal
complexes. We found t230 to be the most frequent spa-type,
in agreement with a recent publication by Grundmann et al.60
All but one of the PC had the same S. aureus strain in the two
swabs, which is in agreement with other studies.41 If more nasal
swabs had been taken we could perhaps have found more
people who were IC. With the broad genetic diversity of the
isolates it was not possible to correlate any speciﬁc clonal
complex with DEFB103 expression.
DEFB103 genomic copy number for each individual was
determined using P-PRT, and the distribution is in correlation
with other ﬁndings.61 In a healthy population the gene copy
number of DEFB103 varies from 2 to 12 copies, with most
individuals having between 2 and 7 copies.21
TheDEFB103 copy number varied from2 to 8 in all three groups,
and the distribution of DEFB103 gene copies did not differ
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not a marker for nasal S. aureus carriage status.
This study is, to our knowledge, the ﬁrst to show expression
of DEFB103 in nasal secretions. Other studies have been
performed for hBD-1 and hBD-2 in nasal secretions.62,63 We
found a high degree of variation in expression among the
studied individuals. PC and IC had comparable DEFB103 mRNA
expression to NC, indicating that defensin expression is not up-
regulated in either PC or IC individuals. We observed an inter-
sampling variation in the NC and the IC group in mRNA
expression. This variation could be due to changes in the
environment that affect the expression patterns, but could also
be due to methodological measurement difﬁculties; further we
only looked at S. aureus in the nose and not other bacteria that
could inﬂuence the expression pattern.
A recent study showed a linear correlation between the DEFB4,
encoding human beta-defensin 2, mRNA expression and the DEFB4
copy number in lymphoblastoid cells.21 Other studies by Joly et
al.64 and Janssens et al.25 conﬁrmed these results, but found that
the mRNA expression reached a plateau after 4 or 5 copies of
DEFB4. Fellermann et al. showed that in the range of 2 to 4 copies
there was a logarithmic increase in expression level.23
We were not able to reproduce these results and found no
signiﬁcant correlation between the copy number and the mRNA
expression of DEFB103. Even when we excluded persons with a
copy number above 5 we could not ﬁnd a linear correlation
between CNV and mRNA expression. We only investigated S.
aureus in the nasal samples and not other bacteria, virus or fungi
that could have inﬂuenced the expression levels of DEFB103; this
could perhaps explain the large variation in expression within
the same copy number. Furthermore, functional or regulatory
single nucleotide polymorphisms (SNPs) in the DEFB103 gene or
associated regulatory genes may inﬂuence the expression
patterns,65 and were not included in this study. Also DEFB4,
DEFB103, and DEFB104 are all part of the b-defensin repeat
region and show the same copy number.21 We could not
determine whether one gene or a combination of all three genes
might be involved in susceptibility to nasal S. aureus carriage or
whether SNPs in one gene affect the expression of the other
genes.
The complex interplay between host genetics, epidemiological
risk factors, and bacterial characteristics that results in S. aureus
nasal carriage is difﬁcult to clarify. This study provides tools to
further continue the detailed elucidation of this interplay.
Acknowledgements
Wewould like to thank JohnArmour (University of Nottingham,
UK) and Edward J. Hollox (University of Leicester, UK) for providing
us with copy number control samples. Thanks also to the
laboratory technicians Britta Hansen, Elvira Chapka and Karina
Liebman Madsen for expert technical assistance. This study was
supported by ‘‘Det Sundhedsvidenskabelige Forskningsra˚d’’ and
The Idella Foundation.
Conﬂict of interest: None.
References
1. Boman HG. Innate immunity and the normal microﬂora. Immunol Rev
2000;173:5–16.
2. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol
2003;3:710–20.
3. Lehrer RI. Primate defensins. Nat Rev Microbiol 2004;2:727–38.
4. Bulet P, Stocklin R, Menin L. Anti-microbial peptides: from invertebrates to
vertebrates. Immunol Rev 2004;198:169–84.
5. Schutte BC, Mitros JP, Bartlett JA,Walters JD, Jia HP,WelshMJ, et al. Discovery of
ﬁve conserved beta-defensin gene clusters using a computational search strat-
egy. Proc Natl Acad Sci U S A 2002;99:2129–33.6. Ganz T, Lehrer RI, Defensins. Curr Opin Immunol 1994;6:584–9.
7. Lehrer RI, Ganz T. Defensins: endogenous antibiotic peptides from human
leukocytes. Ciba Found Symp 1992;171:276–90.
8. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol
2002;14:96–102.
9. Selsted ME, Harwig SS, Ganz T, Schilling JW, Lehrer RI. Primary structures of
three human neutrophil defensins. J Clin Invest 1985;76:1436–9.
10. Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, et al. Defensins.
Natural peptide antibiotics of human neutrophils. J Clin Invest 1985;76:
1427–35.
11. Jones DE, Bevins CL. Paneth cells of the human small intestine express an
antimicrobial peptide gene. J Biol Chem 1992;267:23216–25.
12. Fulton C, Anderson GM, Zasloff M, Bull R, Quinn AG. Expression of natural
peptide antibiotics in human skin. Lancet 1997;350:1750–1.
13. Harder J, Bartels J, Christophers E, Schroder JM. Isolation and characterization of
human beta-defensin-3, a novel human inducible peptide antibiotic. J Biol Chem
2001;276:5707–13.
14. Garcia JR, Jaumann F, Schulz S, Krause A, Rodriguez-Jimenez J, Forssmann U,
et al. Identiﬁcation of a novel, multifunctional beta-defensin (human beta-
defensin 3) with speciﬁc antimicrobial activity. Its interaction with plasma
membranes of Xenopus oocytes and the induction of macrophage chemoat-
traction. Cell Tissue Res 2001;306:257–64.
15. Harder J, Bartels J, Christophers E, Schroder JM. A peptide antibiotic fromhuman
skin. Nature 1997;387:861.
16. Bals R,Wang X,Wu Z, Freeman T, Bafna V, Zasloff M, et al. Human beta-defensin
2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest
1998;102:874–80.
17. Jin G, Kawsar HI, Hirsch SA, Zeng C, Jia X, Feng Z, et al. An antimicrobial peptide
regulates tumor-associatedmacrophage trafﬁcking via the chemokine receptor
CCR2, a model for tumorigenesis. PLoS One 2010;5:e10993.
18. Semple F, Webb S, Li HN, Patel HB, Perretti M, Jackson IJ, et al. Human beta-
defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol
2010;40:1073–8.
19. Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, et al. Beta-
defensins: linking innate and adaptive immunity through dendritic and T cell
CCR6. Science 1999;286:525–8.
20. Linzmeier R, Ho CH, Hoang BV, Ganz T. A 450-kb contig of defensin genes on
human chromosome 8p23. Gene 1999;233:205–11.
21. Hollox EJ, Armour JA, Barber JC. Extensive normal copy number variation of a
beta-defensin antimicrobial-gene cluster. Am J Hum Genet 2003;73:591–600.
22. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, et al.
Psoriasis is associated with increased beta-defensin genomic copy number. Nat
Genet 2008;40:23–5.
23. Fellermann K, Stange DE, Schaeffeler E, Schmalzl H,Wehkamp J, Bevins CL, et al.
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2
gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet
2006;79:439–48.
24. Bentley RW, Pearson J, Gearry RB, Barclay ML, McKinney C, Merriman TR, et al.
Association of higher DEFB4 genomic copy number with Crohn’s disease. Am J
Gastroenterol 2010;105:354–9.
25. JanssensW, Nuytten H, Dupont LJ, Van Eldere J, Vermeire S, Lambrechts D, et al.
Genomic copy number determines functional expression of b-defensin 2 in
airway epithelial cells and associates with chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 2010;182:163–9.
26. Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ,
et al. Beta-defensin-2 protein is a serum biomarker for disease activity in
psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS
One 2009;4:e4725.
27. Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998;339:520–32.
28. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus
aureus: epidemiology, underlyingmechanisms, and associated risks. Clin Micro-
biol Rev 1997;10:505–20.
29. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and
importance. Bacteriol Rev 1963;27:56–71.
30. Armstrong-Esther CA. Carriage patterns of Staphylococcus aureus in a healthy
non-hospital population of adults and children. Ann Hum Biol 1976;3:221–7.
31. Hofﬂer U, Bulanda M, Heczko PB, Pulverer G. A comparison of staphylococcal
nasal carrier rates in Germany and Poland. Med Microbiol Immunol
1978;164:285–90.
32. Maxwell JG, Ford CR, Peterson DE, Mitchell CR. Long-term study of nasal
staphylococci among hospital personnel. Am J Surg 1969;118:849–54.
33. Cole AM, Tahk S, Oren A, Yoshioka D, Kim YH, Park A, et al. Determinants of
Staphylococcus aureus nasal carriage. Clin Diagn Lab Immunol 2001;8:1064–9.
34. Peacock SJ, Justice A, Grifﬁths D, de Silva GD, Kantzanou MN, Crook D, et al.
Determinants of acquisition and carriage of Staphylococcus aureus in infancy. J
Clin Microbiol 2003;41:5718–25.
35. Yu VL, Goetz A, Wagener M, Smith PB, Rihs JD, Hanchett J, et al. Staphylococcus
aureus nasal carriage and infection in patients on hemodialysis. Efﬁcacy of
antibiotic prophylaxis. N Engl J Med 1986;315:91–6.
36. Lipsky BA, Pecoraro RE, Chen MS, Koepsell TD. Factors affecting staphylococcal
colonization among NIDDM outpatients. Diabetes Care 1987;10:483–6.
37. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source
of Staphylococcus aureus bacteremia. Study Group. N Engl J Med 2001;344:11–6.
38. WertheimHF, VosMC, Ott A, van BelkumA, Voss A, Kluytmans JA, et al. Risk and
outcome of nosocomial Staphylococcus aureus bacteraemia in nasal carriers
versus non-carriers. Lancet 2004;364:703–5.
P. Fode et al. / International Journal of Infectious Diseases 15 (2011) e388–e394e39439. Nouwen JL, Fieren MW, Snijders S, Verbrugh HA, van Belkum A. Persistent (not
intermittent) nasal carriage of Staphylococcus aureus is the determinant of CPD-
related infections. Kidney Int 2005;67:1084–92.
40. van Belkum A, Verkaik NJ, de Vogel CP, Boelens HA, Verveer J, Nouwen JL, et al.
Reclassiﬁcation of Staphylococcus aureus nasal carriage types. J Infect Dis
2009;199:1820–6.
41. VandenberghMF, Yzerman EP, van BelkumA, Boelens HA, SijmonsM, Verbrugh
HA. Follow-up of Staphylococcus aureus nasal carriage after 8 years: redeﬁning
the persistent carrier state. J Clin Microbiol 1999;37:3133–40.
42. Corrigan RM, Rigby D, Handley P, Foster TJ. The role of Staphylococcus aureus
surface protein SasG in adherence and bioﬁlm formation. Microbiology
2007;153:2435–46.
43. Corrigan RM, Miajlovic H, Foster TJ. Surface proteins that promote adherence of
Staphylococcus aureus to human desquamated nasal epithelial cells. BMCMicro-
biol 2009;9:22.
44. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, Gross M,
et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major
risk factor in nosocomial infections. Nat Med 2004;10:243–5.
45. Noble WC. Carriage of Staphylococcus aureus and beta haemolytic streptococci
in relation to race. Acta Derm Venereol 1974;54:403–5.
46. Noble WC, Valkenburg HA, Wolters CH. Carriage of Staphylococcus aureus in
random samples of a normal population. J Hyg (Lond) 1967;65:567–73.
47. Cole AM, Dewan P, Ganz T. Innate antimicrobial activity of nasal secretions.
Infect Immun 1999;67:3267–75.
48. Picard C, Puel A, BonnetM, Ku CL, Bustamante J, Yang K, et al. Pyogenic bacterial
infections in humans with IRAK-4 deﬁciency. Science 2003;299:2076–9.
49. von BH, Picard C, Jin Z, Pankla R, Xiao H, Ku CL, et al. Pyogenic bacterial
infections in humans with MyD88 deﬁciency. Science 2008;321:691–6.
50. van den Akker EL, Nouwen JL, Melles DC, van Rossum EF, Koper JW, Uitterlinden
AG, et al. Staphylococcus aureus nasal carriage is associated with glucocorticoid
receptor gene polymorphisms. J Infect Dis 2006;194:814–8.
51. EmontsM, Uitterlinden AG, Nouwen JL, Kardys I, MaatMP,Melles DC, et al. Host
polymorphisms in interleukin 4, complement factor H, and C-reactive protein
associatedwith nasal carriage of Staphylococcus aureus and occurrence of boils. J
Infect Dis 2008;197:1244–53.
52. Nouwen JL, Ott A, Kluytmans-Vandenbergh MF, Boelens HA, Hofman A, van BA,
et al. Predicting the Staphylococcus aureus nasal carrier state: derivation and
validation of a ‘culture rule’. Clin Infect Dis 2004;39:806–11.
53. Armour JA, Palla R, Zeeuwen PL, den Heijer M, Schalkwijk J, Hollox EJ. Accurate,
high-throughput typing of copy number variation using paralogue ratios from
dispersed repeats. Nucleic Acids Res 2007;35:e19.54. Aldhous MC, Abu Baker S, Prescott NJ, Palla R, Soo K, Mansﬁeld JC, et al.
Measurement methods and accuracy in copy number variation: failure to
replicate associations of beta-defensin copy number with Crohn’s disease.
Hum Mol Genet 2010;19:4930–8.
55. Groth M, Szafranski K, Taudien S, Huse K, Mueller O, Rosenstiel P, et al.
High-resolution mapping of the 8p23.1 beta-defensin cluster reveals strictly
concordant copy number variation of all genes. Hum Mutat 2008;29:
1247–54.
56. Perne A, Zhang X, Lehmann L, Groth M, Stuber F, Book M. Comparison of
multiplex ligation-dependent probe ampliﬁcation and real-time PCR accuracy
for gene copy number quantiﬁcation using the beta-defensin locus. Biotechni-
ques 2009;47:1023–8.
57. WertheimHF, Melles DC, VosMC, van LeeuwenW, van BelkumA, Verbrugh HA,
et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect
Dis 2005;5:751–62.
58. Eriksen NH, Espersen F, Rosdahl VT, Jensen K. Carriage of Staphylococcus aureus
among 104 healthy persons during a 19-month period. Epidemiol Infect
1995;115:51–60.
59. Larsen AR, Goering R, Stegger M, Lindsay JA, Gould KA, Hinds J, et al. Two
distinct clones of methicillin-resistant Staphylococcus aureus (MRSA) with the
same USA300 pulsed-ﬁeld gel electrophoresis proﬁle: a potential pitfall for
identiﬁcation of USA300 community-associated MRSA. J Clin Microbiol
2009;47:3765–8.
60. Grundmann H, Aanensen DM, van den Wijngaard CC, Spratt BG, Harmsen D,
Friedrich AW. Geographic distribution of Staphylococcus aureus causing inva-
sive infections in Europe: a molecular-epidemiological analysis. PLoS Med
2010;7:e1000215.
61. Hollox EJ. Copy number variation of beta-defensins and relevance to disease.
Cytogenet Genome Res 2008;123:148–55.
62. Chen PH, Fang SY. Expression of human beta-defensin 2 in human nasal
mucosa. Eur Arch Otorhinolaryngol 2004;261:238–41.
63. Dauletbaev N, Gropp R, Frye M, Loitsch S, Wagner TO, Bargon J. Expression of
human beta defensin (HBD-1 and HBD-2) mRNA in nasal epithelia of adult
cystic ﬁbrosis patients, healthy individuals, and individuals with acute cold.
Respiration 2002;69:46–51.
64. Joly S, Organ CC, Johnson GK, McCray Jr PB, Guthmiller JM. Correlation between
beta-defensin expression and induction proﬁles in gingival keratinocytes. Mol
Immunol 2005;42:1073–84.
65. Groth M, Wiegand C, Szafranski K, Huse K, Kramer M, Rosenstiel P, et al. Both
copy number and sequence variations affect expression of human DEFB4. Genes
Immun 2010;11:458–66.
